about
Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathyDiabetic macular edema: Current management 2013Ranibizumab for the treatment of degenerative ocular conditions.Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab InjectionAnti-angiogenic Therapy for Retinal Disease.Bilateral same-session intravitreal injections of anti-vascular endothelial growth factors.Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
P2860
Q26823985-B077E1A2-9585-4363-A467-35C3F211EB54Q28262797-DC098D43-69F6-4D5F-AAF9-89045366E068Q31146850-83D71D79-0A6F-44E7-B3EB-8359E0FB5124Q33831237-753A016B-75BF-41BB-AABF-1D3DEA7F4D00Q35897929-4134558B-3101-4A60-9284-05A2C9CA8616Q38805247-50756C5A-379D-4C99-8996-B60AD729E138Q41649671-BA8E5724-9093-4162-A9A0-B3AB790A3506Q42442066-43234F7C-41FC-49BC-9F1E-8C0814F04EFC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ranibizumab in diabetic macular edema
@en
Ranibizumab in diabetic macular edema.
@nl
type
label
Ranibizumab in diabetic macular edema
@en
Ranibizumab in diabetic macular edema.
@nl
prefLabel
Ranibizumab in diabetic macular edema
@en
Ranibizumab in diabetic macular edema.
@nl
P2093
P2860
P356
P1476
Ranibizumab in diabetic macular edema
@en
P2093
Akrit Sodhi
Claudia Krispel
Xiaoban Xin
P2860
P304
P356
10.4239/WJD.V4.I6.310
P577
2013-12-01T00:00:00Z